Cargando…
Weaker Effects of the Fourth Dose of BNT162b2 SARS-CoV-2 Vaccine on the Elderly Human Population
The vaccines presently available are less effective in older people due to senescence of their immune systems. We measured the antibody responses of 42 adults living in nursing homes after the third and the fourth doses of an mRNA vaccine and found that the strain (BA.2 and BA.2.75: from 64 to 128,...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301649/ https://www.ncbi.nlm.nih.gov/pubmed/37376484 http://dx.doi.org/10.3390/vaccines11061095 |
_version_ | 1785064862786781184 |
---|---|
author | Dimeglio, Chloé Da-Silva, Isabelle Porcheron, Marion Panero, Marie-Pierre Staes, Laetitia Trémeaux, Pauline Villars, Hélène Izopet, Jacques |
author_facet | Dimeglio, Chloé Da-Silva, Isabelle Porcheron, Marion Panero, Marie-Pierre Staes, Laetitia Trémeaux, Pauline Villars, Hélène Izopet, Jacques |
author_sort | Dimeglio, Chloé |
collection | PubMed |
description | The vaccines presently available are less effective in older people due to senescence of their immune systems. We measured the antibody responses of 42 adults living in nursing homes after the third and the fourth doses of an mRNA vaccine and found that the strain (BA.2 and BA.2.75: from 64 to 128, BA.5: from 16 to 32, BQ.1.1: from 16 to 64 among the uninfected) influenced the effect of the fourth dose of vaccine on neutralizing antibodies. The fourth dose also increased binding antibodies (from 1036 BAU/mL to 5371 BAU/mL among the uninfected, from 3700 BAU/mL to 6773 BAU/mL among the BA.5 infected). This effect was less significant than that of the third dose of vaccine for both neutralizing (BA.2: from 8 to 128, BA.5: from 2 to 16, BA.2.75: from 8 to 64, BQ.1.1: from 2 to 16) and binding antibodies (from 139.8 BAU/mL to 2293 BAU/mL). However, the fourth dose attained the 5000 BAU/mL threshold conferring approximately 80% protection against a SARS-CoV-2 BA.2 infection in most individuals, unlike the third. |
format | Online Article Text |
id | pubmed-10301649 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103016492023-06-29 Weaker Effects of the Fourth Dose of BNT162b2 SARS-CoV-2 Vaccine on the Elderly Human Population Dimeglio, Chloé Da-Silva, Isabelle Porcheron, Marion Panero, Marie-Pierre Staes, Laetitia Trémeaux, Pauline Villars, Hélène Izopet, Jacques Vaccines (Basel) Brief Report The vaccines presently available are less effective in older people due to senescence of their immune systems. We measured the antibody responses of 42 adults living in nursing homes after the third and the fourth doses of an mRNA vaccine and found that the strain (BA.2 and BA.2.75: from 64 to 128, BA.5: from 16 to 32, BQ.1.1: from 16 to 64 among the uninfected) influenced the effect of the fourth dose of vaccine on neutralizing antibodies. The fourth dose also increased binding antibodies (from 1036 BAU/mL to 5371 BAU/mL among the uninfected, from 3700 BAU/mL to 6773 BAU/mL among the BA.5 infected). This effect was less significant than that of the third dose of vaccine for both neutralizing (BA.2: from 8 to 128, BA.5: from 2 to 16, BA.2.75: from 8 to 64, BQ.1.1: from 2 to 16) and binding antibodies (from 139.8 BAU/mL to 2293 BAU/mL). However, the fourth dose attained the 5000 BAU/mL threshold conferring approximately 80% protection against a SARS-CoV-2 BA.2 infection in most individuals, unlike the third. MDPI 2023-06-12 /pmc/articles/PMC10301649/ /pubmed/37376484 http://dx.doi.org/10.3390/vaccines11061095 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Dimeglio, Chloé Da-Silva, Isabelle Porcheron, Marion Panero, Marie-Pierre Staes, Laetitia Trémeaux, Pauline Villars, Hélène Izopet, Jacques Weaker Effects of the Fourth Dose of BNT162b2 SARS-CoV-2 Vaccine on the Elderly Human Population |
title | Weaker Effects of the Fourth Dose of BNT162b2 SARS-CoV-2 Vaccine on the Elderly Human Population |
title_full | Weaker Effects of the Fourth Dose of BNT162b2 SARS-CoV-2 Vaccine on the Elderly Human Population |
title_fullStr | Weaker Effects of the Fourth Dose of BNT162b2 SARS-CoV-2 Vaccine on the Elderly Human Population |
title_full_unstemmed | Weaker Effects of the Fourth Dose of BNT162b2 SARS-CoV-2 Vaccine on the Elderly Human Population |
title_short | Weaker Effects of the Fourth Dose of BNT162b2 SARS-CoV-2 Vaccine on the Elderly Human Population |
title_sort | weaker effects of the fourth dose of bnt162b2 sars-cov-2 vaccine on the elderly human population |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301649/ https://www.ncbi.nlm.nih.gov/pubmed/37376484 http://dx.doi.org/10.3390/vaccines11061095 |
work_keys_str_mv | AT dimegliochloe weakereffectsofthefourthdoseofbnt162b2sarscov2vaccineontheelderlyhumanpopulation AT dasilvaisabelle weakereffectsofthefourthdoseofbnt162b2sarscov2vaccineontheelderlyhumanpopulation AT porcheronmarion weakereffectsofthefourthdoseofbnt162b2sarscov2vaccineontheelderlyhumanpopulation AT paneromariepierre weakereffectsofthefourthdoseofbnt162b2sarscov2vaccineontheelderlyhumanpopulation AT staeslaetitia weakereffectsofthefourthdoseofbnt162b2sarscov2vaccineontheelderlyhumanpopulation AT tremeauxpauline weakereffectsofthefourthdoseofbnt162b2sarscov2vaccineontheelderlyhumanpopulation AT villarshelene weakereffectsofthefourthdoseofbnt162b2sarscov2vaccineontheelderlyhumanpopulation AT izopetjacques weakereffectsofthefourthdoseofbnt162b2sarscov2vaccineontheelderlyhumanpopulation |